KOMBINATIONSTHERAPIE, EINSCHLIESSLICH EINES KRAS-G12C-INHIBITORS UND EINES ODER MEHRERER ZUSÄTZLICHER PHARMAZEUTISCHER WIRKSTOFFE FÜR DIE BEHANDLUNG VON KREBS

European patent · EP3883579 · In force

Register entry

Publication number
EP3883579
Application number
EP19886683
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Nov 18, 2019
Published
Sep 29, 2021
Granted
Dec 24, 2025
Protection ends at the latest
Nov 17, 2039
Next annual fee due
Nov 30, 2026
IPC classes
A61K 31/555 (2006.01)
A61K 31/506 (2006.01)
A61K 31/519 (2006.01)
A61K 45/06 (2006.01)
A61P 35/00 (2006.01)
A61K 39/395 (2006.01)
C07K 16/28 (2006.01)
Priority
US 201862769355 P 19.11.2018
US 201962821376 P 20.03.2019
US 201962865819 P 24.06.2019
PCT application
PCT/US2019/062064 18.11.2019
PCT publication
WO2020/106647 28.05.2020
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Dec 24, 2025

    Granted

    Specification status
    Non-published patent application → Granted patent
    Status of protective title
    Initiated → Active

    Published in Swissreg on 24.12.2025

Parties

Holder

Amgen Inc.

One Amgen Center Drive, Thousand Oaks CA 91320, US

Inventor

LIPFORD, James Russell

Thousand Oaks, CA 91320-1799, US

CANON, Jude Robert

Thousand Oaks, CA 91320-1799, US

SAIKI, Anne Y.

Thousand Oaks, CA 91320-1799, US

REX, Karen Louise

Thousand Oaks, CA 91320-1799, US

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.